ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype

Chimeric Antigen Receptor (CAR) T-cell therapies have emerged as an effective and potentially curative immunotherapy for patients with relapsed or refractory malignancies. Treatment with CD19 CAR T-cells has shown unprecedented results in hematological malignancies, including heavily refractory leuk...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreno-Cortes, Eider, Franco-Fuquen, Pedro, Garcia-Robledo, Juan E., Forero, Jose, Booth, Natalie, Castro, Januario E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502212/
https://www.ncbi.nlm.nih.gov/pubmed/37719008
http://dx.doi.org/10.3389/fonc.2023.1200914

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502212/
https://www.ncbi.nlm.nih.gov/pubmed/37719008
http://dx.doi.org/10.3389/fonc.2023.1200914

Ejemplares similares